Literature DB >> 23468504

Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules.

Sarah Dion1, Maryline Bourgine, Ophélie Godon, Florence Levillayer, Marie-Louise Michel.   

Abstract

Hepatitis B virus (HBV) persistence may be due to impaired HBV-specific immune responses being unable to eliminate efficiently or cure infected hepatocytes. The immune mechanisms that lead to HBV persistence have not been completely identified, and no appropriate animal model is available for such studies. Therefore, we established a chronic HBV infection model in a mouse strain with human leukocyte antigen A2/DR1 (HLA-A2/DR1) transgenes and an H-2 class I/class II knockout. The liver of these mice was transduced with adeno-associated virus serotype 2/8 (AAV2/8) carrying a replication-competent HBV DNA genome. In all AAV2/8-transduced mice, hepatitis B virus surface antigen, hepatitis B virus e antigen, and HBV DNA persisted in serum for at least 1 year. Viral replication intermediates and transcripts were detected in the livers of the AAV-injected mice. The hepatitis B core antigen was expressed in 60% of hepatocytes. No significant inflammation was observed in the liver. This was linked to a higher number of regulatory T cells in liver than in controls and a defect in HBV-specific functional T-cell responses. Despite the substantial tolerance resulting from expression of HBV antigens in hepatocytes, we succeeded in priming functional HBV-specific T-cell responses in peripheral tissues, which subsequently reached the liver. This AAV2/8-HBV-transduced HLA-A2/DR1 murine model recapitulates virological and immunological characteristics of chronic HBV infection, and it could be useful for the development of new treatments and immune-based therapies or therapeutic vaccines for chronic HBV infections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23468504      PMCID: PMC3648192          DOI: 10.1128/JVI.03134-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects.

Authors:  Anthony Pajot; Marie-Louise Michel; Maryline Mancini-Bourgine; Marie-Noelle Ungeheuer; David M Ojcius; Qiang Deng; François A Lemonnier; Yu-Chun Lone
Journal:  Microbes Infect       Date:  2006-09-12       Impact factor: 2.700

2.  Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.

Authors:  Ou Cao; Eric Dobrzynski; Lixin Wang; Sushrusha Nayak; Bethany Mingle; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2007-04-16       Impact factor: 22.113

3.  Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Authors:  Shih-Wen Lin; Scott E Hensley; Nia Tatsis; Marcio O Lasaro; Hildegund C J Ertl
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

4.  Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.

Authors:  Jeroen N Stoop; Renate G van der Molen; Carla C Baan; Luc J W van der Laan; Ernst J Kuipers; Johannes G Kusters; Harry L A Janssen
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

5.  Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.

Authors:  Dongping Xu; Junliang Fu; Lei Jin; Hui Zhang; Chunbao Zhou; Zhengsheng Zou; Jing-Min Zhao; Bin Zhang; Ming Shi; Xilai Ding; Zirong Tang; Yang-Xin Fu; Fu-Sheng Wang
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

6.  Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B.

Authors:  Jeroen N Stoop; Renate G van der Molen; Ernst J Kuipers; Johannes G Kusters; Harry L A Janssen
Journal:  Virology       Date:  2006-12-20       Impact factor: 3.616

7.  Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection.

Authors:  Ornella Franzese; Patrick T F Kennedy; Adam J Gehring; Jim Gotto; Roger Williams; Mala K Maini; Antonio Bertoletti
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection.

Authors:  Li-Rung Huang; Hui-Lin Wu; Pei-Jer Chen; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-09       Impact factor: 11.205

9.  Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver.

Authors:  Ekaterina Breous; Suryanarayan Somanathan; Luk H Vandenberghe; James M Wilson
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

10.  A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.

Authors:  Anthony Pajot; Marie-Louise Michel; Nicolas Fazilleau; Véronique Pancré; Claude Auriault; David M Ojcius; François A Lemonnier; Yu-Chun Lone
Journal:  Eur J Immunol       Date:  2004-11       Impact factor: 5.532

View more
  47 in total

1.  Viral hepatitis: The bumpy road to animal models for HBV infection.

Authors:  Ulrike Protzer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-04-12       Impact factor: 46.802

2.  Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.

Authors:  Yingjie Bian; Zheng Zhang; Zhichen Sun; Juanjuan Zhao; Danming Zhu; Yang Wang; Sherry Fu; Jingya Guo; Longchao Liu; Lishan Su; Fu-Sheng Wang; Yang-Xin Fu; Hua Peng
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

3.  Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Authors:  Carolina Chiale; Safiehkhatoon Moshkani; John K Rose; Michael D Robek
Journal:  Antiviral Res       Date:  2019-05-30       Impact factor: 5.970

4.  Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation.

Authors:  Yang Zeng; Tongtong Gao; Guangyu Zhao; Yuting Jiang; Yi Yang; Hong Yu; Zhihua Kou; Yuchun Lone; Shihui Sun; Yusen Zhou
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

5.  Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model.

Authors:  Marvin M Festag; Julia Festag; Simon P Fräßle; Theresa Asen; Julia Sacherl; Sophia Schreiber; Martin A Mück-Häusl; Dirk H Busch; Karin Wisskirchen; Ulrike Protzer
Journal:  Mol Ther       Date:  2019-02-10       Impact factor: 11.454

Review 6.  Mouse models for therapeutic vaccination against hepatitis B virus.

Authors:  Claudia Dembek; Ulrike Protzer
Journal:  Med Microbiol Immunol       Date:  2014-12-19       Impact factor: 3.402

7.  A mouse model for HBV immunotolerance and immunotherapy.

Authors:  Dan Yang; Longchao Liu; Danming Zhu; Hua Peng; Lishan Su; Yang-Xin Fu; Liguo Zhang
Journal:  Cell Mol Immunol       Date:  2013-09-30       Impact factor: 11.530

8.  A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.

Authors:  Safiehkhatoon Moshkani; Carolina Chiale; Sabine M Lang; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

Review 9.  Modeling hepatitis B virus infection, immunopathology and therapy in mice.

Authors:  Liang Cheng; Feng Li; Moses T Bility; Christopher M Murphy; Lishan Su
Journal:  Antiviral Res       Date:  2015-06-19       Impact factor: 5.970

10.  Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination.

Authors:  Danming Zhu; Longchao Liu; Dan Yang; Sherry Fu; Yingjie Bian; Zhichen Sun; Junming He; Lishan Su; Liguo Zhang; Hua Peng; Yang-Xin Fu
Journal:  J Immunol       Date:  2016-03-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.